TY - JOUR
T1 - Regorafenib for the treatment of advanced gastric cancer (INTEGRATE)
T2 - A multinational placebo-controlled phase II Trial
AU - Pavlakis, Nick
AU - Sjoquist, Katrin M.
AU - Martin, Andrew J.
AU - Tsobanis, Eric
AU - Yip, Sonia
AU - Kang, Yoon Koo
AU - Bang, Yung Jue
AU - Alcindor, Thierry
AU - O'Callaghan, Christopher J.
AU - Burnell, Margot J.
AU - Tebbutt, Niall C.
AU - Rha, Sun Young
AU - Lee, Jeeyun
AU - Cho, Jae Yong
AU - Lipton, Lara R.
AU - Wong, Mark
AU - Strickland, Andrew
AU - Kim, Jin Won
AU - Zalcberg, John R.
AU - Simes, John
AU - Goldstein, David
N1 - Funding Information:
National Health and Medical Research Council (NHMRC) Program Grant No. 1037786
Publisher Copyright:
© 2016 by American Society of Clinical Oncology.
PY - 2016/8/10
Y1 - 2016/8/10
N2 - Purpose We evaluated the activity of regorafenib, an oral multikinase inhibitor, in advanced gastric adenocarcinoma. Patients and Methods We conducted an international (Australia and New Zealand, South Korea, and Canada) randomized phase II trial in which patients were randomly assigned at a two-To-one ratio and stratified by lines of prior chemotherapy for advanced disease (one v two) and region. Eligible patients received best supportive care plus regorafenib 160 mg or matching placebo orally on days 1 to 21 of each 28-day cycle until disease progression or prohibitive adverse events occurred. The primary end point was progression-free survival (PFS). Final analysis included data to December 31, 2014. Results A total of 152 patients were randomly assigned from November 7, 2012, to February 25, 2014, yielding 147 evaluable patients (regorafenib, n = 97; placebo, n = 50). Baseline characteristics were balanced. Median PFS significantly differed between groups (regorafenib, 2.6 months; 95% CI, 1.8 to 3.1 and placebo, 0.9 months; 95% CI, 0.9 to 0.9; hazard ratio [HR], 0.40; 95% CI, 0.28 to 0.59; P <.001). The effect was greater in South Korea than in Australia, New Zealand, and Canada combined (HR, 0.12 v 0.61; interaction P < .001) but consistent across age, neutrophil-To-lymphocyte ratio, primary site, lines of chemotherapy, peritoneal metastasis presence, number of metastatic sites, and plasma vascular endothelial growth factor A. A survival trend in favor of regorafenib was seen (median, 5.8 months; 95% CI, 4.4 to 6.8 v 4.5 months; 95% CI, 3.4 to 5.2; HR, 0.74; P = .147). Twenty-nine patients assigned to placebo received open-label regorafenib after disease progression. Regorafenib toxicity was similar to that previously reported. Conclusion In this phase II trial, regorafenib was effective in prolonging PFS in refractory advanced gastric adenocarcinoma. Regional differences were found, but regorafenib was effective in both regional groups. A phase III trial is planned.
AB - Purpose We evaluated the activity of regorafenib, an oral multikinase inhibitor, in advanced gastric adenocarcinoma. Patients and Methods We conducted an international (Australia and New Zealand, South Korea, and Canada) randomized phase II trial in which patients were randomly assigned at a two-To-one ratio and stratified by lines of prior chemotherapy for advanced disease (one v two) and region. Eligible patients received best supportive care plus regorafenib 160 mg or matching placebo orally on days 1 to 21 of each 28-day cycle until disease progression or prohibitive adverse events occurred. The primary end point was progression-free survival (PFS). Final analysis included data to December 31, 2014. Results A total of 152 patients were randomly assigned from November 7, 2012, to February 25, 2014, yielding 147 evaluable patients (regorafenib, n = 97; placebo, n = 50). Baseline characteristics were balanced. Median PFS significantly differed between groups (regorafenib, 2.6 months; 95% CI, 1.8 to 3.1 and placebo, 0.9 months; 95% CI, 0.9 to 0.9; hazard ratio [HR], 0.40; 95% CI, 0.28 to 0.59; P <.001). The effect was greater in South Korea than in Australia, New Zealand, and Canada combined (HR, 0.12 v 0.61; interaction P < .001) but consistent across age, neutrophil-To-lymphocyte ratio, primary site, lines of chemotherapy, peritoneal metastasis presence, number of metastatic sites, and plasma vascular endothelial growth factor A. A survival trend in favor of regorafenib was seen (median, 5.8 months; 95% CI, 4.4 to 6.8 v 4.5 months; 95% CI, 3.4 to 5.2; HR, 0.74; P = .147). Twenty-nine patients assigned to placebo received open-label regorafenib after disease progression. Regorafenib toxicity was similar to that previously reported. Conclusion In this phase II trial, regorafenib was effective in prolonging PFS in refractory advanced gastric adenocarcinoma. Regional differences were found, but regorafenib was effective in both regional groups. A phase III trial is planned.
UR - http://www.scopus.com/inward/record.url?scp=84981717709&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84981717709&partnerID=8YFLogxK
U2 - 10.1200/JCO.2015.65.1901
DO - 10.1200/JCO.2015.65.1901
M3 - Article
C2 - 27325864
AN - SCOPUS:84981717709
SN - 0732-183X
VL - 34
SP - 2728
EP - 2735
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 23
ER -
